Evidence outlook
Approved: Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (4)
- Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) TRUXIMA, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
- Pemphigus Vulgaris (PV) TRUXIMA is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
- Non-Hodgkin's Lymphoma (NHL)
- Truxima: NHL, CLL, rheumatoid arthritis, GPA/MPA
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02149121 NCT02149121 · Rheumatoid Arthritis This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value. Registry: NCT02149121 | 3 | Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period) 2016-01 | Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other CD20 drugs
Obinutuzumab, Ocrelizumab, Ocrevus Zunovo, Ofatumumab, PF-05280586 and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rituximab-Abbs (Truxima): this drug | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| Ocrelizumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| ABP 692 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bexobrutideg | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Nemtabrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab Beta (Bejescin) | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.